RxDoctor Payments Data

Lincoln Chin, MD

Neurology · Fort Worth, TXNPI 1710920749

Payments from drug & device makers

$14,300in general payments, 2019–2025

Across 795 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novartis$1K
  • Biogen$1K
  • Acadia Pharmaceuticals Inc$746
  • Teva Pharmaceuticals USA, Inc.$712
  • UCB, Inc.$622
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$430%
  • Food & beverage$14,257100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)240$3,591
Novartis81$1,308
Biogen60$1,181
Acadia Pharmaceuticals Inc37$746
Teva Pharmaceuticals USA, Inc.38$712
UCB, Inc.23$622
Amgen(2 entities)16$408
EMD Serono, Inc.12$406
Lilly USA, LLC14$301
Supernus Pharmaceuticals, Inc.36$293
Merz Pharmaceuticals, LLC10$285
GE HealthCare15$285
Genentech USA, Inc.12$266
Eisai Inc.11$263
Pfizer12$262
Bristol Myers Squibb16$231
AstraZeneca8$193
Neurocrine Biosciences, Inc.7$184
Upsher-smith Laboratories LLC10$178
Argenx US, Inc.7$177
SK Life Science, Inc.8$163
Lundbeck LLC7$134
CSL Behring5$119
Sunovion Pharmaceuticals Inc.14$107
Nevro Corp.5$107
ANI Pharmaceuticals, Inc.4$101
Johnson & Johnson6$92
Takeda Pharmaceuticals U.S.A., Inc.4$82
Grifols USA, LLC5$77
Akcea Therapeutics, Inc.3$77
Adamas Pharmaceuticals, Inc.4$75
Jazz Pharmaceuticals Inc.4$73
Tanabe Pharma America, Inc.4$72
Kyowa Kirin, Inc.3$70
Catalyst Pharmaceuticals, Inc.3$66
Sanofi3$63
MDD US Operations, LLC3$62
TG Therapeutics, Inc.2$59
Avion Pharmaceuticals3$58
Amneal Pharmaceuticals LLC3$51
Portola Pharmaceuticals, LLC2$50
Scilex Pharmaceuticals Inc.2$49
Merz North America, Inc.1$46
Acorda Therapeutics, Inc2$43
Boston Scientific2$40
Greenwich Biosciences, Inc.2$35
Corium, LLC2$34
Almatica Pharma LLC2$32
Currax Pharmaceuticals LLC2$27
Springworks Therapeutics, Inc.1$25
Alnylam Pharmaceuticals Inc.1$25
Immedica Pharma US, Inc.1$24
Arbor Pharmaceuticals, Inc.2$24
Abbott1$24
Otsuka America Pharmaceutical, Inc.1$22
Banner Life Sciences, LLC1$20
Aprecia Pharmaceuticals, LLC1$18
Azurity Pharmaceuticals, Inc.1$18
Aquestive Therapeutics, Inc.1$17
Inspire Medical Systems, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,300 in reported general payments places this provider in the 70th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$120,325
Medicare patients
266
Services billed
4,773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab40$376,950
VumerityDiroximel Fumarate14$121,438
Avonex Pen (4 Pack)Interferon Beta-1a13$104,473
BotoxOnabotulinumtoxina31$33,612
Glatiramer Acetate12$32,256
RexultiBrexpiprazole15$25,286
Oxtellar XrOxcarbazepine11$11,118
Memantine Hcl293$6,142
Lacosamide18$5,795
Levetiracetam125$4,177
Gabapentin165$3,488
Donepezil Hcl359$2,882
Carbidopa-LevodopaCarbidopa/Levodopa97$2,096
Carbamazepine24$1,432
Eletriptan HbrEletriptan Hydrobromide13$1,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$1,181$121,43814 claims
AbbVieBotox$3,591$33,61231 claims
Otsuka America Pharmaceutical, Inc.Rexulti$22$25,28615 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$293$11,11811 claims
Upsher-smith Laboratories LLCTopiramate$178$71156 claims
Almatica Pharma LLCSertraline Hcl$32$15921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,246 neurology providers in Texas.

Other neurology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →